Post-operative Adjuvant Therapy w/wo GammaTile + Systemic Therapy
To compare surgical tumor removal and GammaTile therapy followed by adjuvant systemic therapy (bevacizumab or lomustine) to surgical tumor removal followed by adjuvant systemic therapy (bevacizumab or lomustine) without GammaTile therapy.
Glioblastoma
DEVICE: Gamma Tile-Surgically Targeted Radiation Therapy (STaRT)|RADIATION: Stereotactic Radiation Therapy
Median Overall Survival (OS) from the time of surgery up to 2 years post surgery., Analysis of primary outcome measure will include the intent to treat population., up to 2 years
Overall Survival, A measure of median overall survival for the per protocol population, up to 2 years|Progression free survival (PFS), A measure of time from surgery to any failure, local or distant., up to 2 years|Change in Quality of Life (QOL), Functional Assessment of Cancer Therapy-Brain (FACT-Br), up to 1.5 years|Assessment of Neurocognitive Function, Hopkins Verbal Learning Test-Revised \[HVLT-R\], up to 1.5 years|Functional Status-Karnofsky Performance Scale (KPS), An assessment of functional impairment. Score 0 to 100, with 100 being no impairment of performance, up to 2 years|Proportion of subjects with evidence of radiation necrosis (RN), A measure of patients who experience radiation necrosis post-surgery., up to 2 years|Proportion of subjects with evidence of surgical site wound infection, A measure of patients who experience surgical site wound infection, Up to 1.5 months|Proportion of subjects with evidence of a surgical site dural closure-related cerebral spinal fluid (CSF) leak, A measure of patients who experience surgical site dural closure-related cerebral spinal fluid (CSF) leak, Up to 1.5 months|Post-surgery length of hospital stay of study subjects, A measure in days of the length of hospital stay post surgery., Up to 1.5 months|Rate of re-admission, A measure of patients re-admitted to the hospital +/- 30 days post surgery., Up to 1 month
To compare surgical tumor removal and GammaTile therapy followed by adjuvant systemic therapy (bevacizumab or lomustine) to surgical tumor removal followed by adjuvant systemic therapy (bevacizumab or lomustine) without GammaTile therapy.